title: The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis.
abstract: The role of tachykinin NK-1 receptors in the area postrema (AP) in emesis was examined in ferrets. Strong c-fos-like immunoreactivity was observed in the AP and nucleus tractus solitalius (NTS) in cisplatin (10 mg/kg, i.p.)-treated animals, but not in control animals. The number of the central emetogen morphine-induced vomits and retches was remarkably reduced (95%) and that of the peripheral emetogen copper sulphate-induced vomits was significantly (54%) reduced by AP lesion. Pretreatment with the tachykinin NK-1 receptor antagonists HSP-117 (1.0 microg) and CP-99,994 (7.5 microg) into the AP decreased the numbers of vomits and retches induced by morphine and copper sulphate. These results suggest that NK-1 receptors in the AP are involved in the mechanism of emesis induced by morphine and copper sulphate.
authors.affiliation: Department of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, 814-0180, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ariumi
authors.forename: R
authors.initials: R
authors.lastname: Saito
authors.forename: S
authors.initials: S
authors.lastname: Nago
authors.forename: M
authors.initials: M
authors.lastname: Hyakusoku
authors.forename: Y
authors.initials: Y
authors.lastname: Takano
authors.forename: H
authors.initials: H
authors.lastname: Kamiya
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001572:Benzofurans / Q000494:pharmacology; D002628:Chemoreceptor Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology; D019327:Copper Sulfate / Q000494:pharmacology; D004347:Drug Interactions / Q000502:physiology; D005289:Ferrets; D020546:Fourth Ventricle / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D008526:Medulla Oblongata / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D009020:Morphine / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology; D064729:Neurokinin-1 Receptor Antagonists; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects / Q000378:metabolism; D011869:Radioligand Assay; D018040:Receptors, Neurokinin-1 / Q000187:drug effects* / Q000378:metabolism*; D017552:Solitary Nucleus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D013373:Substance P / Q000378:metabolism / Q000494:pharmacology; D015320:Tachykinins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014316:Tritium; D014839:Vomiting / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D001572:Benzofurans; D009294:Narcotics; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D016760:Proto-Oncogene Proteins c-fos; D018040:Receptors, Neurokinin-1; D015320:Tachykinins; D014316:Tritium; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; D013373:Substance P; D009020:Morphine; C119466:HSP 117; D019327:Copper Sulfate; D002945:Cisplatin